{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,19]],"date-time":"2026-02-19T00:42:20Z","timestamp":1771461740034,"version":"3.50.1"},"reference-count":32,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2001,10,1]],"date-time":"2001-10-01T00:00:00Z","timestamp":1001894400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2001,10,1]],"date-time":"2001-10-01T00:00:00Z","timestamp":1001894400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["ajkd.org","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["American Journal of Kidney Diseases"],"published-print":{"date-parts":[[2001,10]]},"DOI":"10.1053\/ajkd.2001.27391","type":"journal-article","created":{"date-parts":[[2008,3,17]],"date-time":"2008-03-17T23:33:20Z","timestamp":1205796800000},"page":"S20-S25","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":22,"special_numbering":"S","title":["Effect of erythropoietin on cardiovascular diseases"],"prefix":"10.1053","volume":"38","author":[{"given":"Gere","family":"Sunder-Plassmann","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Walter H","family":"H\u00f6rl","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"suppl 3","key":"10.1053\/ajkd.2001.27391_BIB1","doi-asserted-by":"crossref","first-page":"S112","DOI":"10.1053\/ajkd.1998.v32.pm9820470","article-title":"Clinical epidemiology of cardiovascular disease in chronic renal disease","volume":"32","author":"Foley","year":"1998","journal-title":"Am J Kidney Dis"},{"key":"10.1053\/ajkd.2001.27391_BIB2","doi-asserted-by":"crossref","first-page":"2597","DOI":"10.1093\/ndt\/12.12.2597","article-title":"Incidence and risk factors of atherosclerotic cardiovasclar accidents in predialysis chronic renal failure patients: A prospective study","volume":"12","author":"Jungers","year":"1997","journal-title":"Nephrol Dial Transplant"},{"key":"10.1053\/ajkd.2001.27391_BIB3","doi-asserted-by":"crossref","first-page":"1277","DOI":"10.1093\/ndt\/11.7.1277","article-title":"Outcome and risk factors for left ventricular disorders in chronic uremia","volume":"11","author":"Parfrey","year":"1996","journal-title":"Nephrol Dial Transplant"},{"key":"10.1053\/ajkd.2001.27391_BIB4","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1016\/S0272-6386(96)90357-1","article-title":"Prevalent left ventricular hypertrophy in the predialysis population: Identifying opportunities for intervention","volume":"27","author":"Levin","year":"1996","journal-title":"Am J Kidney Dis"},{"key":"10.1053\/ajkd.2001.27391_BIB5","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/S0272-6386(96)90130-4","article-title":"The impact of anemia on cardiomyopathy, morbidity, and mortality in end-stage renal disease","volume":"28","author":"Foley","year":"1996","journal-title":"Am J Kidney Dis"},{"key":"10.1053\/ajkd.2001.27391_BIB6","doi-asserted-by":"crossref","first-page":"973","DOI":"10.1038\/ki.1987.94","article-title":"Uremic cardiomyopathy: An inadequate left ventricular hypertrophy","volume":"31","author":"London","year":"1987","journal-title":"Kidney Int"},{"key":"10.1053\/ajkd.2001.27391_BIB7","doi-asserted-by":"crossref","first-page":"878","DOI":"10.1038\/ki.1989.274","article-title":"Vascular changes in hemodialysis patients in response to recombinant human erythropoietin","volume":"36","author":"London","year":"1989","journal-title":"Kidney Int"},{"key":"10.1053\/ajkd.2001.27391_BIB8","first-page":"26","article-title":"Echocardiographic findings in patients on maintenance hemodialysis substituted with recombinant human erythropoietin","volume":"31","author":"L\u00f6w","year":"1989","journal-title":"Clin Nephrol"},{"key":"10.1053\/ajkd.2001.27391_BIB9","first-page":"1","article-title":"Regression of left ventricular hypertrophy in dialysis patients following correction of anemia with recombinant human erythropoietin","volume":"6","author":"Silberberg","year":"1990","journal-title":"Can J Cardiol"},{"key":"10.1053\/ajkd.2001.27391_BIB10","doi-asserted-by":"crossref","first-page":"1309","DOI":"10.1038\/ki.1993.383","article-title":"Cardiovascular consequences of the correction of the anemia of renal failure with erythropoietin","volume":"44","author":"Fellner","year":"1993","journal-title":"Kidney Int"},{"key":"10.1053\/ajkd.2001.27391_BIB11","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1159\/000187315","article-title":"Follow-up of changes induced by anemia compensation in normotensive hemodialysis patients with left ventricular hypertrophy","volume":"64","author":"Wizemann","year":"1993","journal-title":"Nephron"},{"key":"10.1053\/ajkd.2001.27391_BIB12","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1016\/S0272-6386(97)90335-8","article-title":"Cardiovascular effects of recombinant human erythropoietin in predialysis patients","volume":"29","author":"Portoles","year":"1997","journal-title":"Am J Kidney Dis"},{"key":"10.1053\/ajkd.2001.27391_BIB13","doi-asserted-by":"crossref","first-page":"1079","DOI":"10.1038\/ki.1992.390","article-title":"Reduced capillary density in the myocardium of uremic rats-A stereological study","volume":"42","author":"Amann","year":"1992","journal-title":"Kidney Int"},{"key":"10.1053\/ajkd.2001.27391_BIB14","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1159\/000169007","article-title":"Cardiovascular effects of increasing hemoglobin in chronic renal failure","volume":"16","author":"Mayer","year":"1996","journal-title":"Am J Nephrol"},{"key":"10.1053\/ajkd.2001.27391_BIB15","doi-asserted-by":"crossref","first-page":"1425","DOI":"10.1093\/ndt\/15.9.1425","article-title":"Effects of hemoglobin normalization on quality of life and cardiovascular parameters in end-stage renal failure","volume":"15","author":"McMahon","year":"2000","journal-title":"Nephrol Dial Transplant"},{"key":"10.1053\/ajkd.2001.27391_BIB16","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1093\/ndt\/6.1.31","article-title":"Reversal of left ventricular hypertrophy following recombinant human erythropoietin treatment of anaemic dialysed uraemic patients","volume":"6","author":"Cannella","year":"1991","journal-title":"Nephrol Dial Transplant"},{"key":"10.1053\/ajkd.2001.27391_BIB17","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1016\/S0272-6386(99)70118-6","article-title":"Left ventricular mass index increase in early renal disease: Impact of decline in hemoglobin","volume":"34","author":"Levin","year":"1999","journal-title":"Am J Kidney Dis"},{"key":"10.1053\/ajkd.2001.27391_BIB18","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1016\/0140-6736(90)90733-L","article-title":"Long-term cardiorespiratory effects of amelioration of renal anaemia by erythropoietin","volume":"335","author":"Macdougall","year":"1990","journal-title":"Lancet"},{"key":"10.1053\/ajkd.2001.27391_BIB19","first-page":"280","article-title":"Regression left ventricular hypertrophy after partial correction of anemia with erythropoietin in patients on hemodialysis: A prospective study","volume":"35","author":"Pascual","year":"1991","journal-title":"Clin Nephrol"},{"key":"10.1053\/ajkd.2001.27391_BIB20","doi-asserted-by":"crossref","first-page":"1325","DOI":"10.1046\/j.1523-1755.2000.00289.x","article-title":"Effect of hemoglobin levels in hemodialysis patients with asymptomatic cardiomyopathy","volume":"58","author":"Foley","year":"2000","journal-title":"Kidney Int"},{"key":"10.1053\/ajkd.2001.27391_BIB21","doi-asserted-by":"crossref","first-page":"1921","DOI":"10.1681\/ASN.V8121921","article-title":"Anemia in hemodialysis patients: Variables affecting this outcome predictor","volume":"8","author":"Madore","year":"1997","journal-title":"J Am Soc Nephrol"},{"key":"10.1053\/ajkd.2001.27391_BIB22","doi-asserted-by":"crossref","first-page":"610","DOI":"10.1681\/ASN.V103610","article-title":"Hematocrit level and associated mortality in hemodialysis patients","volume":"10","author":"Ma","year":"1999","journal-title":"J Am Soc Nephrol"},{"key":"10.1053\/ajkd.2001.27391_BIB23","doi-asserted-by":"crossref","first-page":"1642","DOI":"10.1093\/ndt\/13.7.1642","article-title":"The impact of haematocrit levels and eryththropoietin treatment on overall and cardiovascular mortality and morbidity-The experience of the Lombardy Dialysis Registry","volume":"13","author":"Locatelli","year":"1998","journal-title":"Nephrol Dial Transplant"},{"key":"10.1053\/ajkd.2001.27391_BIB24","doi-asserted-by":"crossref","first-page":"584","DOI":"10.1056\/NEJM199808273390903","article-title":"The effects of normal as compared with low hematocrit values patients with cardiac disease who are receiving hemodialysis and epoetin","volume":"339","author":"Besarab","year":"1998","journal-title":"N Engl J Med"},{"key":"10.1053\/ajkd.2001.27391_BIB25","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1159\/000188803","article-title":"Increased risk of cardiovascular disease with erythropoietin in chronic dialysis patients","volume":"72","author":"Iseki","year":"1996","journal-title":"Nephron"},{"key":"10.1053\/ajkd.2001.27391_BIB26","doi-asserted-by":"crossref","first-page":"1737","DOI":"10.1016\/S0735-1097(00)00613-6","article-title":"The use of subcutaneous erythropoietin and intravenous iron for the treatment of the anemia of severe, resistant congestive heart failure improves cardiac and renal function and functional cardiac class, and markedly reduces hospitalizations","volume":"35","author":"Silverberg","year":"2000","journal-title":"J Am Coll Cardiol"},{"key":"10.1053\/ajkd.2001.27391_BIB27","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1038\/ki.1990.19","article-title":"Aortic and large artery compliance in end-stage renal failure","volume":"37","author":"London","year":"1990","journal-title":"Kidney Int"},{"key":"10.1053\/ajkd.2001.27391_BIB28","doi-asserted-by":"crossref","first-page":"2434","DOI":"10.1161\/01.CIR.99.18.2434","article-title":"Impact of aortic stiffness on survival in end-stage renal disease","volume":"99","author":"Blacher","year":"1999","journal-title":"Circulation"},{"key":"10.1053\/ajkd.2001.27391_BIB29","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1681\/ASN.V9197","article-title":"Hemodynamic and hormonal changes during erythropoietin therapy in hemodialysis patients","volume":"9","author":"Lebel","year":"1998","journal-title":"J Am Soc Nephrol"},{"key":"10.1053\/ajkd.2001.27391_BIB30","doi-asserted-by":"crossref","first-page":"975","DOI":"10.1038\/ki.1992.376","article-title":"Effects of oxygen breathing and erythropoietin on hypoxic vasodilatation in uremic anemia","volume":"42","author":"Roger","year":"1992","journal-title":"Kidney Int"},{"key":"10.1053\/ajkd.2001.27391_BIB31","doi-asserted-by":"crossref","first-page":"2877","DOI":"10.1093\/ndt\/13.11.2877","article-title":"Acute effects of recombinant human erythropoietin on plasma levels of proendothelin-1 and endothelin-1 in haemodialysis patients","volume":"13","author":"Kang","year":"1998","journal-title":"Nephrol Dial Transplant"},{"issue":"suppl 4","key":"10.1053\/ajkd.2001.27391_BIB32","first-page":"S8","article-title":"European Best Practice Guidelines 1-4: Evaluating anaemia and initiating treatment","volume":"15","author":"Valderr\u00e1bano","year":"2000","journal-title":"Nephrol Dial Transplant"}],"container-title":["American Journal of Kidney Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0272638601088862?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0272638601088862?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,3]],"date-time":"2025-10-03T01:22:27Z","timestamp":1759454547000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0272638601088862"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2001,10]]},"references-count":32,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2001,10]]}},"alternative-id":["S0272638601088862"],"URL":"https:\/\/doi.org\/10.1053\/ajkd.2001.27391","relation":{},"ISSN":["0272-6386"],"issn-type":[{"value":"0272-6386","type":"print"}],"subject":[],"published":{"date-parts":[[2001,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Effect of erythropoietin on cardiovascular diseases","name":"articletitle","label":"Article Title"},{"value":"American Journal of Kidney Diseases","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1053\/ajkd.2001.27391","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"converted-article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2001 National Kidney Foundation, Inc. Published by Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}